WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413969
CAS#: 7054-25-3
Description: Quinidine gluconate is an antimalarial schizonticide and an antiarrhythmic agent with class 1a activity;
Hodoodo Cat#: H413969
Name: Quinidine gluconate
CAS#: 7054-25-3
Chemical Formula: C26H36N2O9
Exact Mass: 0.00
Molecular Weight: 520.580
Elemental Analysis: C, 59.99; H, 6.97; N, 5.38; O, 27.66
Related CAS #: 747-45-5 (bisulfate) 27555-34-6 (polygalacturonate) 56-54-2 (free base) 1668-99-1 (HCl) 7054-25-3 (gluconate)
Synonym: Quinidine gluconate; Duraquin
IUPAC/Chemical Name: Cinchonan-9-ol, 6'-methoxy-, (9S)-, mono-D-gluconate (salt)
InChi Key: XHKUDCCTVQUHJQ-LCYSNFERSA-N
InChi Code: InChI=1S/C20H24N2O2.C6H12O7/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;7-1-2(8)3(9)4(10)5(11)6(12)13/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;2-5,7-11H,1H2,(H,12,13)/t13-,14-,19+,20-;2-,3-,4+,5-/m01/s1
SMILES Code: C=C[C@@H](C[N@@]1CC2)[C@@H]2C[C@@H]1[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34.O[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 520.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Covinsky JO, Russo J Jr, Kelly KL, Cashman J, Amick EN, Mason WD. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers. J Clin Pharmacol. 1979 May-Jun;19(5-6):261-9. doi: 10.1002/j.1552-4604.1979.tb02479.x. PMID: 469022.
2: Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum. 1995 Apr;24(5):315-22. doi: 10.1016/s0049-0172(95)80003-4. PMID: 7604299.
3: Darbar D, Dell'Orto S, Wilkinson GR, Roden DM. Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Am J Health Syst Pharm. 1996 Mar 15;53(6):655-8. doi: 10.1093/ajhp/53.6.655. PMID: 8800971.
4: Taggart WV, Holyoak W. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate. Clin Ther. 1983;5(4):357-64. PMID: 6871920.
5: Ueda CT, Williamson BJ, Dzindzio BS. Absolute quinidine bioavailability. Clin Pharmacol Ther. 1976 Sep;20(3):260-5. doi: 10.1002/cpt1976203260. PMID: 954347.
6: Russo J Jr, Russo ME, Smith RA, Pershing LK. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing. J Clin Pharmacol. 1982 May-Jun;22(5-6):264-70. doi: 10.1002/j.1552-4604.1982.tb02672.x. PMID: 7107973.
7: Guharoy SR, Shahin J, Levin S. Quinidine-induced hepatotoxicity revisited. Vet Hum Toxicol. 1991 Dec;33(6):613-4. PMID: 1808844.
8: Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm. 1988 Oct;45(10):2079-91. Erratum in: Am J Hosp Pharm 1989 May;46(5):922. PMID: 3228079.
9: Falk RH, O'Brien JL. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias. Chest. 1984 Oct;86(4):537-40. doi: 10.1378/chest.86.4.537. PMID: 6383741.
10: St-Onge JM, Sirois G, Gagnon MA. Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state. Eur J Drug Metab Pharmacokinet. 1983 Oct-Dec;8(4):363-72. doi: 10.1007/BF03188768. PMID: 6673973.
